Primary Cutaneous Mucinous Carcinoma of the Eyelid

Primary cutaneous mucinous carcinoma (PCMC) is a rare low-grade malignant neoplasm derived from the eccrine glands. PCMC most commonly arises in the head and neck, with the eyelid being the most common site of origin. This case report describes a 51-year-old male with a painless, pigmented superficial nodular lesion over his right lower eyelid. The lesion was considered to be benign, and the initial treatment was simple excision with a 3-mm margin. However, histologic examination revealed the diagnosis of PCMC, and the patient underwent re-excision of the tumor site with an additional 3-mm margin from the initial scar. Histologic study of this second margin was free of any malignant cells. The patient experienced no postoperative complication or recurrence after 2 years. In our case, the skin lesion had benign morphologic findings and was strongly suspected to be a benign mass. Physicians should be aware of this tumor and be able to differentiate it from benign cystic or solid eyelid lesions.

Primary Cutaneous Mucinous Carcinoma of the Eyelid

Primary cutaneous mucinous carcinoma (PCMC) is a rare low-grade malignant neoplasm derived from the eccrine glands. PCMC most commonly arises in the head and neck, with the eyelid being the most common site of origin. This case report describes a 51-year-old male with a painless, pigmented superficial nodular lesion over his right lower eyelid. The lesion was considered to be benign, and the initial treatment was simple excision with a 3-mm margin. However, histologic examination revealed the diagnosis of PCMC, and the patient underwent re-excision of the tumor site with an additional 3-mm margin from the initial scar. Histologic study of this second margin was free of any malignant cells. The patient experienced no postoperative complication or recurrence after 2 years. In our case, the skin lesion had benign morphologic findings and was strongly suspected to be a benign mass. Physicians should be aware of this tumor and be able to differentiate it from benign cystic or solid eyelid lesions.

Nonexcisional, Minimally Invasive Rejuvenation of the Neck Using Radiofrequency Tissue Tightening (FaceTite(TM))

BACKGROUND: Noninvasive radiofrequency (RF) and lasers have been used for skin tightening and body contouring since the 1990s. The safety, efficacy, and patient satisfaction with the procedure using a novel RF device (BodyTite(TM); Invasix Ltd, Yokneam Ilit, Israel) were evaluated. METHODS: We retrospectively included 13 patients who were treated with the BodyTite(TM) to rejuvenate neck skin from May 2012 to May 2014. The power of the device was set between 10 and 15 W. The target temperature was set at 38degrees C. Three independent evaluators were asked to grade baseline and 6- to 12-month follow-up photographs using a comprehensive quantitative 4-point laxity grading scale. All patients were asked to rate their satisfaction with the aesthetic outcome and quality of life after treatment. RESULTS: Grading results of baseline and follow-up photographs of patients were statistically significant with an average grade improvement of 1.01 points on the 4 point scale. Using a patient satisfaction scale, patients were also significantly more satisfied (poor, 0%; fair, 15%; good, 46%; and excellent, 39%). There were transient complications, such as minimal erythema, mild edema, and focal hardness, which resolved spontaneously within 1 week. There were no significant adverse effects or complications. CONCLUSIONS: The BodyTite(TM) is a minimally invasive, RF treatment that was demonstrated to improve skin laxity without significant adverse effects or complications. The BodyTite(TM) provides a nonsurgical option for the safe and effective rejuvenation of neck skin under local anesthesia.

Local Flap Surgical Scar Management Caused by Skin Cancer Using Fractional CO2 Laser Treatment

BACKGROUND: Despite careful and atraumatic surgical techniques, surgical treatment and reconstruction can result in scarring. Scar from skin cancer on the face may continue for a long time. This current report demonstrates the utility of a fractional CO2 laser to treat facial scar resulting from local flap coverage to remove skin cancer. METHODS: Five patients underwent local flap coverage after removing facial skin cancer tumors. The resulting scars after reconstruction of these skin cancer defects are on face. Each received 6 treatments with a fractional CO2 laser device (LineXel(R); UTI Co. Ltd, Seoul, Korea). Treatments were spaced about 1 month apart. Results were evaluated before the initial treatment, and at 1 month after the last treatment session. RESULTS: The fractional CO2 laser device is effective for treating surgical scars especially on scar texture and thickness without significant adverse effects. Prior to the laser session, these scars concerned different pigmentation, pliability, height, vascularity compared to the surrounding skin. Patients also expressed a 4-point subjective scale of satisfaction. Patients were satisfied with the treated scars. CONCLUSIONS: The fractional CO2 laser device of the present report is an effective treatment modality for facial scars after reconstruction of skin cancer defects. Besides this laser also does not show any serious adverse effect.